NCT00372385View on ClinicalTrials.gov

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

PHASE2CompletedINTERVENTIONAL
Enrollment

334

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

June 30, 2008

Conditions
Chronic Hepatitis C
Interventions
DRUG

Ribavirin

tablet

DRUG

Pegylated Interferon Alfa 2a

Solution for injection

DRUG

Placebo

tablet

DRUG

Telaprevir

tablet

Trial Locations (4)

Unknown

Call For Information, Call For Information

Call For Information, Call For Information

Call For Information, Call For Information

Call for Information, Call For Information

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT00372385 - Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C | Biotech Hunter | Biotech Hunter